Dr. Reddy's Launches World's First Aranesp Biosimilar In India, Vows To Bring Out More
This article was originally published in The Pink Sheet Daily
Executive Summary
The Indian drug maker has officially kept its biosimilar pipeline secret but has indicated that it includes a pegylated molecule in late-stage clinical trials, two other products scheduled to enter clinical trials, and several others in early stage development.
You may also be interested in...
ESA REMS Allows Oncology Providers One Year To Enroll Before Possible Distribution Limits
The Risk Evaluation and Mitigation Strategy for erythropoiesis-stimulating agents announced by FDA Feb. 16 focuses on requiring health care providers to educate patients about the risks and benefits of treatment.
India's Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10
HYDERABAD, India - Enthused by the success of its first monoclonal antibody Reditux - a copy of Genentech's Rituxan (rituximab) - India's Dr. Reddy's Labs is making a full throttle attempt to develop and launch copies of most blockbuster biotech drugs available in the international markets
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.